Cardiff Oncology, Inc.
Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing onvansertib, an oral and highly selective PLK1 inhibitor, for cancer indications with high unmet medical need. The company’s core approach is to combine onvansertib with standard-of-care therapies and use biomarker-driven patient selection to improve response rates. Its lead development efforts are centered on RAS-mutated metastatic colorectal cancer, with additional investigator-initiated studies in pancreatic cancer, small cell lung cancer, triple negative breast cancer, and CMML. Cardiff Oncology is still pre-commercial and depends on clinical progress, regulatory success, and external financing to advance its pipeline.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueOnvansertib, an oral small-molecule PLK1 inhibitor being developed for multiple cancers.
Combination trials pairing onvansertib with standard-of-care therapies in selected tumor types.
Tumor genomics and biomarker assays used to refine patient selection and response assessment.
Sales-based or usage-based royalties from other intellectual property licenses unrelated to onvansertib.
Customers
Cardiff Oncology does not sell an approved commercial drug today, so its direct economic counterparties are primarily clinical trial sites, investigators, contract manufacturers, and licensing partners rather than end-patient customers. The company’s future commercial customers would be oncologists and healthcare systems treating patients with RAS-mutated mCRC and other difficult-to-treat cancers, if onvansertib is approved. In the current stage, the company also receives small royalty payments from licensees of other intellectual property, which are unrelated to its oncology pipeline. Because the business is still in development, success depends on trial enrollment, investigator support, and eventual physician adoption rather than traditional product sales.
Academic and community oncology centers enroll patients, run protocols, and generate the clinical data needed to advance onvansertib.
Patients with RAS-mutated metastatic colorectal cancer and other advanced cancers participate in trials because standard options are limited.
If approved, oncologists and cancer centers would use onvansertib in combination regimens for biomarker-selected patients.
Third parties using licensed IP generate small royalty revenue unrelated to the lead oncology program.
Strategy
The company’s strategy is to validate onvansertib as a differentiated PLK1 inhibitor in biomarker-defined cancer populations, starting with RAS-mutated metastatic colorectal cancer. It is pursuing combination regimens with standard-of-care therapies because that approach can improve the probability of clinical benefit and support a clearer regulatory path. Cardiff Oncology is also broadening evidence generation through investigator-initiated trials in pancreatic cancer, small cell lung cancer, triple negative breast cancer, and CMML to expand the addressable opportunity. Protecting intellectual property, improving patient selection with genomics, and maintaining access to external capital are central to the strategy because the company remains pre-commercial and cash-consuming.
The lead indication is the clearest path to value creation and potential partnering or approval.
Additional data in other cancers can support platform credibility and optionality.
The company has substantial doubt about continuing as a going concern without additional capital.
Geography
Cardiff Oncology is headquartered in the United States and is listed on Nasdaq Capital Market under CRDF. Its development and regulatory activities are primarily U.S.-based, including clinical work at U.S. institutions such as Dana-Farber Cancer Institute and U.S. patent protection from the USPTO. The company also notes that its business is subject to foreign regulation, which matters because clinical supply, trial operations, and future commercialization may involve non-U.S. jurisdictions. No country-level revenue disclosure was provided in the excerpts, and the company currently has minimal revenue from royalties rather than geographic product sales.
Risks
Cardiff Oncology is a clinical-stage company with no approved product revenue, so its business depends on successful trial outcomes, regulatory clearance, and future commercialization of onvansertib. The company explicitly states it has incurred losses since inception, has a substantial accumulated deficit, and faces substantial doubt about its ability to continue as a going concern, which makes financing risk a central issue. Clinical development risk is high because oncology trials are expensive, slow, and uncertain, and competing therapies from much larger companies could reduce the commercial opportunity even if onvansertib shows activity. The company also relies on third-party manufacturers and distributors, so supply disruptions, GMP compliance failures, or raw-material sourcing issues could delay trials and increase costs. As a biotech developer, it also faces regulatory, IP, cybersecurity, and healthcare compliance risks that can materially affect timelines and valuation.
- Clinical development failureImpact: CriticalLikelihood: High
The lead asset is still in development, and efficacy or safety results may not support approval or partnering.
Exposure: Onvansertib oncology pipeline
- Insufficient capital / going concernImpact: CriticalLikelihood: High
The company expects its current resources to fund operations only into the first quarter of 2027 and has disclosed substantial doubt about continuing as a going concern.
Exposure: Corporate liquidity
- Regulatory approval and complianceImpact: HighLikelihood: High
Drug development is subject to extensive FDA and foreign regulation, and noncompliance can delay or block development.
Exposure: Clinical and future commercial programs
- Third-party manufacturing dependenceImpact: HighLikelihood: Medium
The company does not own manufacturing capacity and relies on GMP contract manufacturers for clinical supply.
Exposure: Clinical trial supply chain
- Competition from larger oncology developersImpact: HighLikelihood: Medium
Better-funded competitors may develop safer, more effective, or cheaper therapies in the same indications.
Exposure: mCRC and other oncology markets
Accounting
Judgemental itemsManagement estimates CRO and vendor services received but not yet invoiced, which can materially affect R&D expense and liabilities.
Impact: Quarterly operating loss and balance sheet accruals
Revenue from unrelated IP licenses depends on licensee sales activity and timing, creating quarter-to-quarter volatility.
Impact: Small but variable revenue line
Non-cash equity awards are a common expense in development-stage biotech companies and can materially affect reported losses.
Impact: Operating expense and net loss
Liquidity disclosures and runway assumptions are critical because the company expects to need additional capital before commercialization.
Impact: Investor assessment of solvency and financing risk
Similar listed companies
Publicly listed companies with a comparable business focus.
Erasca, Inc.
ERAS · Pharmaceutical Preparations
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Black Diamond Therapeutics, Inc.
BDTX · Biological Products, (No Diagnostic Substances)
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Zentalis Pharmaceuticals, Inc.
ZNTL · Pharmaceutical Preparations
Zentalis Pharmaceuticals is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule cancer therapies.
Last updated: 24/09/2026